{"title":"Schnitzler Syndrome after COVID-19 Vaccination","authors":"Mizuki Asako, H. Matsunaga, K. Oka, S. Ueda","doi":"10.2169/internalmedicine.9598-22","DOIUrl":null,"url":null,"abstract":"An 86-year-old Japanese woman was referred for an examination of leukocytosis and diagnosed with Waldenström macroglobulinemia. She was asymptomatic and remained stable during follow-up without treatment. The day after receiving her first COVID-19 vaccination (Pfizer-BioNTech), she developed urticarial exanthema on her limbs. Although the rash improved with topical steroids, it worsened the day after she received the second vaccination; bone pain, general fatigue, and leukocytosis (white blood cell count: 11,600/ μL) also developed. A skin biopsy showed perivascular and interstitial neutrophil infiltrate with leukocytoclasia (Picture A, B), and definite Schnitzler syndrome was diagnosed according to the Strasbourg criteria (1). She rapidly responded to low-dose prednisolone (10 mg/day), and the skin rash and systemic symptoms resolved. Schnitzler syndrome is autoinflammatory and characterized by urticarial rash and immunoglobulin M monoclonal gammopathy. Lymphoproliferative disorders feature immune dysregulation that often results in autoimmune disease (2). In patients with lymphoproliferative disorders, physicians should pay careful attention to immune complications after COVID-19 vaccination.","PeriodicalId":77259,"journal":{"name":"Medicina interna (Bucharest, Romania : 1991)","volume":"46 3","pages":"2397 - 2397"},"PeriodicalIF":0.0000,"publicationDate":"2022-05-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Medicina interna (Bucharest, Romania : 1991)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2169/internalmedicine.9598-22","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 2
Abstract
An 86-year-old Japanese woman was referred for an examination of leukocytosis and diagnosed with Waldenström macroglobulinemia. She was asymptomatic and remained stable during follow-up without treatment. The day after receiving her first COVID-19 vaccination (Pfizer-BioNTech), she developed urticarial exanthema on her limbs. Although the rash improved with topical steroids, it worsened the day after she received the second vaccination; bone pain, general fatigue, and leukocytosis (white blood cell count: 11,600/ μL) also developed. A skin biopsy showed perivascular and interstitial neutrophil infiltrate with leukocytoclasia (Picture A, B), and definite Schnitzler syndrome was diagnosed according to the Strasbourg criteria (1). She rapidly responded to low-dose prednisolone (10 mg/day), and the skin rash and systemic symptoms resolved. Schnitzler syndrome is autoinflammatory and characterized by urticarial rash and immunoglobulin M monoclonal gammopathy. Lymphoproliferative disorders feature immune dysregulation that often results in autoimmune disease (2). In patients with lymphoproliferative disorders, physicians should pay careful attention to immune complications after COVID-19 vaccination.